Expert Committee Finds Akcea’s NDA for Rare Genetic Disease is Safe and Effective

Drug Industry Daily
A A
An FDA advisory committee voted 12 to 8 Thursday that Akcea Therapeutics’ NDA for treatment of a rare genetic disease demonstrated safety and efficacy.

To View This Article:

Login

Subscribe To Drug Industry Daily